Wall Street Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Wall Street Associates’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$621K	Sell	16,400 -112,000	-87%	-$4.24M	0.41%	89
2016 Q3	$4.85M	Buy	128,400 +107,900	+526%	+$2.38M	1.65%	2
2016 Q2	$361K	Hold	20,500	–	–	0.14%	152
2016 Q1	$249K	Hold	20,500	–	–	0.1%	203
2015 Q4	$499K	Hold	20,500	–	–	0.14%	206
2015 Q3	$364K	Sell	20,500 -223,500	-92%	-$4.05M	0.07%	258
2015 Q2	$4.31M	Sell	244,000 -9,700	-4%	-$178K	0.41%	85
2015 Q1	$7.95M	Sell	253,700 -8,700	-3%	-$252K	0.75%	35
2014 Q4	$7.66M	Sell	262,400 -4,400	-2%	-$112K	0.73%	43
2014 Q3	$5.52M	Sell	266,800 -34,400	-11%	-$678K	0.57%	67
2014 Q2	$7.46M	Buy	301,200 +2,100	+0.7%	+$36.4K	0.64%	53
2014 Q1	$6.34M	Sell	299,100 -11,400	-4%	-$230K	0.52%	74
2013 Q4	$5.58M	Buy	+310,500	New	+$4.04M	0.46%	76

Other funds holding AERI

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wall Street Associates's AERI Position: Q4 2016 in Review

Wall Street Associates reduced its Aerie Pharmaceuticals (AERI) stake by 87% in Q4 2016, selling an estimated $4.24M and leaving 16,400 shares worth $621K. The position accounts for 0.41% of the portfolio, ranked #89.

Wall Street Associates first reported a position in AERI in Q4 2013 and has held it in 13 quarters since. The position peaked at $7.95M in Q1 2015. 151 funds tracked by Wall St. Rank hold AERI as of Q4 2016.

Wall Street Associates held 16,400 shares of Aerie Pharmaceuticals worth $621K as of Q4 2016.
Wall Street Associates sold 112,000 Aerie Pharmaceuticals shares in Q4 2016, an estimated $4.24M.
Aerie Pharmaceuticals made up 0.41% of Wall Street Associates's portfolio in Q4 2016, its #89 holding.
Wall Street Associates first reported a position in Aerie Pharmaceuticals in Q4 2013 and has held it in 13 quarters since.
Wall Street Associates's Aerie Pharmaceuticals position peaked at $7.95M in Q1 2015.
151 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.